iShares MSCI Japan ETF vs Tilray Brands Inc — how do they compare? iShares MSCI Japan ETF trades at $97.39 (market cap $23.87B), while Tilray Brands Inc trades at $3.61 (market cap $530.54M). The key difference: iShares MSCI Japan ETF is far larger — about 45× Tilray Brands Inc's market cap, and iShares MSCI Japan ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Tilray Brands Inc for 31 Days on average.
| EWJ | TLRY | |
|---|---|---|
Market Cap | $23.87B | $530.54M |
Volume | 5,412,820 | 9,099,075 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $21.00 |
52-Week Low | $78.36 | $3.57 |
Typical Hold Time | 56 Days | 31 Days |
Enterprise Value | — | $684.46M |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $98.32, down 1.01% on the day amid broader Asian market pressures. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. Recent news highlights Japan's monetary policy shifts with BOJ rate hikes and yen volatility creating both opportunities and challenges for Japanese equities. The ETF has demonstrated strong performance in 2026, outperforming the S&P 500 with gains exceeding 20% according to Zacks Investment Research (September 30, 2026).
The outlook for EWJ remains constructive given Japan's economic reforms and AI sector growth, though rising bond yields and currency fluctuations present near-term headwinds. Institutional interest appears strong as Japan's market rotation toward technology and AI plays supports continued ETF inflows. Key risks include BOJ policy uncertainty and global interest rate dynamics that could pressure Japanese equities.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →